Skip to main content

Stem Cell, Drug Discovery, and Analytical Services

REPROCELL's services help stem cell and drug discovery scientists around the world advance their preclinical and clinical research.

By Your Area of Expertise

For Cell Therapy Developers

For Stem Cell Researchers

For Diagnostic Developers

For Preclinical Drug Developers

For Clinical Drug Developers

By REPROCELL Service Area

Clinical Stem Cell Services

 We provide end-to-end support for your cell therapy project, from sourcing clinically and commercially consented human tissues to GMP-compliant manufacturing. Using our proprietary non-integrating StemRNA™ Reprogramming Technology, we generate clinical iPSC Seed Clones that meet FDA, EMA, and PMDA standards. These clones can be expanded in a GMP environment to create Master Cell Banks (MCBs) for further cell therapy manufacturing. We provide GMP MCB services for iPSCs, iMSCs (iPSC-derived MSCs), and MSCs (also known as Mesenchymal Stem Cells, Mesenchymal Stromal Cells, or Medicinal Signalling Cells) at our GMP facility in Beltsville, USA, and through our European partner, Histocell. 

FAQs:

Research Stem Cell Services

 We have a complete portfolio of services for the reprogramming and differentiation of high-quality induced pluripotent stem cells (iPSCs). Our research stem cell services include donor recruitment, target cell isolation, iPSC reprogramming, expansion, characterization, neuronal differentiation, and gene editing. Using our proprietary RNA based technology, our services and products for stem cell scientists are used by leading pharmaceutical and biotechnology companies as well as top academic and government research institutions all around the world. 

Regenerative Medicine Products

REPROCELL is advancing the research and development of a wide range of therapies using stem cells and immune cells, with the aim of realizing next‑generation medicine tailored to each individual patient.

Our current lineup includes the adipose‑derived mesenchymal stem cell product Stemchymal® for spinocerebellar degeneration; iPS cell‑derived neural glial progenitor cells (iGRP) targeting central nervous system disorders such as ALS and TM; and, TIL therapy and Glypican‑1 CAR‑T therapy as cell‑based immunotherapies for cancer.

Through the development of these therapies, REPROCELL is striving to bring new treatment options into practical use as quickly as possible.

StemEdit License-Free Gene Editing Solutions

StemEdit is REPROCELL's integrated, license-free gene editing platform that combines AI-designed genome editing with clinically aligned iPSC technologies to support programs from early discovery through clinical translation. Built around StemRNA™ Reprogramming Technology and powered by the AI-designed StemEdit OC-1 nuclease, StemEdit enables high-precision genome engineering with reduced off-target activity, streamlined workflows, and a seamless transition from research-grade editing to clinical-grade iPSC development. 

Whether you need custom gene editing services, reusable Landing Pad Technology, ready-to-use hypoimmune cell lines, or AI-designed gene editing protein for in-house research, StemEdit provides a comprehensive solution for cell therapy developers without licensing restrictions on the editing platform. 

Projects can be performed at REPROCELL's facilities in the United States or Japan, supporting research, translational studies, and GMP-aligned clinical development. 

Precision Medicine Services

Our precision medicine services include our new Pharmacology-AI machine learning platform. Developed in collaboration with IBM and STFC, our automated system rapidly identifies the features driving variation in patient outcomes – streamlining the development of effective patient stratification strategies. Scientists and clinicians with clinical or genomic data can use Pharmacology-AI to identify the key features driving biomarker levels, drug response, or clinical outcome. Our experts can enable IBD researchers to analyze their data via our platform to identify the key ʻomicʼ or clinical features driving differences in drug or biomarker response. We are also developing applications for a number of other organ systems and therapeutic areas. 

Preclinical and Drug Discovery CRO

Our GLP contract research services in human tissues have been trusted by the top pharma and biotech companies since 2002. We provide data that is highly predictive of in vivo drug responses by characterising drug safety, efficacy and absorption in human fresh tissues or bioengineered human tissues, de-risking later clinical trials. Through our extensive clinical networks in the USA and the UK, we have ready access to healthy and diseased human living tissues and organs. We also offer a range of assays in human bioengineered tissue models built on our Alvetex® platform, including models of IBD, skin and IPF, and can create custom assays for your drug discovery programs. 

 

Clinical Laboratory Services

Our integrated network of central laboratories can support your clinical trial sample processing needs across three continents, from our accredited laboratories in the USA, UK, India, and Japan. Our GLP/GCLP and ISO compliant systems are operational 24/7. We offer a range of options including kit preparation, logistics, biospecimen processing and storage, biomarker discovery, and testing. We can coordinate, process, test, and analyze a range of fresh human biospecimens to meet the demands of your clinical research. 

 

Human Tissue Samples

Our global biorepository of human tissue samples provides leading academic and industry researchers with access to over 600,000 human DNA, serum and tissue samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients on four continents. Customers of our human tissue samples and related molecular services include nearly every major pharmaceutical and biotechnology company, as well as top industry, academic, and government research institutions.

Genomic Services

We have more than two decades of experience in extracting nucleic acids from a wide variety of starting materials. We have a large capacity to isolate different nucleic acids from a range of biospecimens, including blood, solid tissues, swabs, and formalin-fixed paraffin embedded blocks. Our preclinical genomic services include DNA and RNA extraction, biomarker discovery and validation, real-time PCR, and next generation sequencing.